DRD3 Ser9Gly Polymorphism and Its Influence on Risperidone Response in Autistic Children

Authors

  • Negar Firouzabadi Pharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, Iran. Department of Pharmacology & Toxicology, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran.
  • Anna Nazariat Department of Pharmacology, School of Pharmacy, Shiraz University of Medical Sciences, International Branch, Shiraz, Iran.
  • Kamiar Zomorrodian Department of Medical Parasitology and Mycology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.

DOI:

https://doi.org/10.18433/J3H63T

Abstract

PURPOSE: Autism, a neuropsychiatric illness, is a complex ailment of mainly indefinite cause. Although precise pathophysiological mechanism is unclear but the role of genetics is undeniable therefore pharmacogenetics may assist to a better management of symptoms. Risperidone is widely used in autism. Considering the significance of dopaminergic system in psychological and neurological diseases and its association with autism, the hypothesis that genetic variant of dopamine receptor (DRD3), Ser9Gly (rs6280), may influence treatment of autism may be assumed. METHOD: In the present study, 56 autistic Persian children within the age range of 2.5 to 14 years were included. Diagnosis of autism was based on DSM-V criteria and the severity degree was measured by ABC-C checklists at base line and after 8 weeks of treatment with risperidone. Based on their scores patients were categorized as responsive and non-responsive groups. DRD3 Ser9Gly (rs6280) was determined by PCR-RFLP. RESULTS: Carriers of Gly allele as well as carriers of Gly/Gly and Ser/Gly genotypes showed significantly better response to risperidone compared with carriers of Ser allele and Ser/Ser genotype (P=0.027; OR= 4.18; 95%CI=1.16-15.03 and P=0.014; OR=6.825; 95%CI=1.36-34.13). CONCLUSION: Our results advocate the possible influence of genetic variation of DRD3 in clinical response to antipsychotics like risperidone in autistic individuals.

 

This article is open to POST-PUBLICATION REVIEW. Registered readers (see “For Readers”) may comment by clicking on ABSTRACT on the issue’s contents page.

Downloads

Download data is not yet available.

Downloads

Published

2018-01-09

How to Cite

Firouzabadi, N., Nazariat, A., & Zomorrodian, K. (2018). DRD3 Ser9Gly Polymorphism and Its Influence on Risperidone Response in Autistic Children. Journal of Pharmacy & Pharmaceutical Sciences, 20(1), 445–452. https://doi.org/10.18433/J3H63T

Issue

Vol. 20 (2017): Pages 319-452

Section

Clinical Pharmacology and Therapeutics

License

This is an open access journal with free of charge non-commercial download. At the time of submission, authors will be asked to transfer the copyright to the accepted article to the Journal of Pharmacy and Pharmaceutical Sciences. The author may purchase the copyright for $500 upon which he/she will have the exclusive copyright to the article. Nevertheless, acceptance of a manuscript for publication in the Journal is with the authors' approval of the terms and conditions of the Creative Commons copyright license Creative Common license (Attribution-ShareAlike) License for non-commercial uses.

CLOCKSS system has permission to collect, preserve, and serve this Archival Unit.